Weekly Research Analysts’ Ratings Changes for ACADIA Pharmaceuticals (ACAD)

by · The Markets Daily

Several brokerages have updated their recommendations and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) in the last few weeks:

  • 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Royal Bank Of Canada from $36.00 to $37.00. They now have an “outperform” rating on the stock.
  • 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Oppenheimer Holdings, Inc. from $23.00 to $25.00. They now have a “market perform” rating on the stock.
  • 8/5/2026 – ACADIA Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..
  • 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Citizens Jmp from $35.00 to $36.00. They now have a “market outperform” rating on the stock.
  • 7/29/2026 – ACADIA Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
  • 7/29/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Bank of America Corporation. They now have a $14.50 price target on the stock.
  • 7/21/2026 – ACADIA Pharmaceuticals had its price target raised by BMO Capital Markets from $34.00 to $36.00. They now have an “outperform” rating on the stock.
  • 7/21/2026 – ACADIA Pharmaceuticals had its price target raised by Stifel Nicolaus from $24.00 to $25.00. They now have a “hold” rating on the stock.
  • 7/7/2026 – ACADIA Pharmaceuticals had its price target raised by Royal Bank Of Canada from $29.00 to $36.00. They now have an “outperform” rating on the stock.
  • 6/30/2026 – ACADIA Pharmaceuticals was downgraded by HC Wainwright from “buy” to “hold”.
  • 6/30/2026 – ACADIA Pharmaceuticals had its price target raised by Bank of America Corporation from $29.00 to $30.00. They now have a “buy” rating on the stock.
  • 6/29/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $37.00 price target on the stock.
  • 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Citigroup Inc. from $32.00 to $35.00. They now have a “buy” rating on the stock.
  • 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $36.00. They now have a “buy” rating on the stock.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 5,401 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total value of $114,393.18. Following the sale, the insider directly owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This represents a 18.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total transaction of $432,660.54. Following the completion of the sale, the executive vice president owned 18,994 shares in the company, valued at $496,313.22. The trade was a 46.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

Featured Stories